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Multiple myeloma (MM) is a plasma-cell (PC) malignancy that is heterogeneous in its clin-
ical presentation and prognosis. Monoclonal gammopathy of undetermined significance
(MGUS) consistently preceded development of MM.The presence of primary IgH translo-
cations and the universal overexpression of cyclin D genes led to a molecular classification
of MM patients into different disease subtypes. Since Bcl-2 family proteins determine
cell fate, we analyzed a publicly available Affymetrix gene expression of 44 MGUS and
414 newly diagnosed MM patients to investigate (1) the global change of Bcl-2 family
members in MM versus MGUS (2) whether the four major subtypes defined as hyper-
diploid, CyclinD1, MAF, and MMSET, display specific apoptotic machineries. We showed
that among the main anti-apoptotic members (Bcl-2, Bcl-xL, and Mcl-1), Mcl-1 up-regulation
discriminated MM from MGUS, in agreement with the prominent role of Mcl-1 in PC dif-
ferentiation. Surprisingly, the expression of multi-domain pro-apoptotic Bak and Bax were
increased during the progression of MGUS to MM. The combined profile of Bcl-2, Bcl-xL,
and Mcl-1 was sufficient to distinguish MM molecular groups. While specific pro-apoptotic
members expression was observed for each MM subtypes, CyclinD1 subgroup, was iden-
tified as a particular entity characterized by a low expression of BH3-only (Puma, Bik, and
Bad) and multi-domain pro-apoptotic members (Bax and Bak). Our analysis supports the
notion that MM heterogeneity is extended to the differential expression of the Bcl-2 family
content in each MM subgroup.The influence of Bcl-2 family profile in the survival of the dif-
ferent patient groups will be further discussed to establish the potential consequences for
therapeutic interventions. Finally, the use of distinct pro-survival members in the different
steps of immune responses to antigen raises also the question of whether the different
Bcl-2 anti-apoptotic profile could reflect a different origin of MM cells.
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INTRODUCTION
Multiple myeloma (MM) is a plasma-cell (PC) malignancy that is
heterogeneous in its clinical presentation and prognosis. Mono-
clonal gammopathy of undetermined significance (MGUS) con-
sistently precedes the development of MM. The presence of
primary IgH translocations and the universal overexpression of
CCND (cyclinD) genes has led to a molecular classification of MM
patients into different disease subtypes (1–3). The main translo-
cations involve the immunoglobulin gene heavy chain locus on
14q32.33 with recurrent chromosome partners. These include
t(11;14), t(4;14), t(14;16), and t(14;20) with an overexpression
of CCND1, MMSET, c-MAF, and MAFB, respectively. Moreover,
half of MM patients do not exhibit IgH translocation but present
multiple trisomies involving chromosomes 3, 5, 7, 9, 11, 15, 19,
and 21 and constitute the hyperdiploid subgroup of MM patients.
Impaired apoptosis is often associated with tumorigenesis and
resistance to treatment. Apoptosis is controlled at multiple levels
and members of the Bcl-2 family regulate the mitochondrial apop-
tosis pathway. They can be divided into three functional groups.
The anti-apoptotic group comprises Bcl-2, Mcl-1, Bcl-xL, A1, and
Bcl-w. These molecules contain four BH-2 homology domains.
The pro-apoptotic multi-domain effectors, Bax and Bak, induce
mitochondria damage upon activation and constitute a second
group (4). Lastly, the BH3-only group, encompasses direct acti-
vators of Bax/Bak (Bid, Bim, and Puma) and sensitizers (Noxa,
Bik, Bad, Hrk, and Bmf), which bind to anti-apoptotic relatives in
order to induce the release of BH3 activators (5).
Individual BH3-only proteins exhibit differential affinities for
their pro-survival counterparts. The activators Bim, Puma, and
Bid bind all pro-survival members with high affinity, whereas
BH3-only sensitizers display more selectivity. For instance, Bad
binds with high affinity only to Bcl-2, Bcl-xL, and Bcl-w, and Noxa
only to Mcl-1 and A1. Bax and Bak also differ in their interac-
tion profile. Bak is tightly bound by Mcl-1 and Bcl-xL but weakly
by Bcl-2 whereas Bax seems to be neutralized by all pro-survival
members (6).
The cellular content of the Bcl-2 family molecules varies among
the different cell types, however it is certain that the interaction
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between anti-apoptotic and pro-apoptotic Bcl-2 members dictates
whether a cell should die or not (4).
Since Bcl-2 family proteins determine cell fate, we analyzed
a publicly available library of Affymetrix gene expression levels
from 44 MGUS and 414 newly diagnosed MM patients to investi-
gate (a) the global change of Bcl-2 family members in MM versus
MGUS and (b) whether the four major MM subtypes, defined
as respectively hyperdiploid (HY) or IgH translocation in 11q13
(CCND1), 16q23 (MAF), and 4p16 (MMSET), display specific
apoptotic machineries.
RESULTS
ANALYSIS OF Bcl-2 FAMILY EXPRESSION BETWEEN MGUS AND MM
We found that among anti-apoptotic members, only Mcl-1
was significantly up-regulated in MM compared to MGUS
(p< 0.0001 Mann–Whitney test; Figure 1) whereas BCL2 and
BCLXL remained unchanged or slightly decreased in MM versus
MGUS (Figure 1). Of note, we excluded BCL2A1 from the study
since it is largely expressed in B cells but lost during PC differen-
tiation. The expression of all BH3-only proteins was not modified
during the progression from MGUS to MM (Figure 2). In contrast,
we observed that the expression of multi-domain pro-apoptotic
BAX and BAK was significantly increased in MM (p= 0.055 and
p< 0.0001 respectively Mann–Whitney test; Figure 1). Altogether,
the major modifications of the Bcl-2 family gene expression dur-
ing the progression of MGUS to MM mainly affected MCL1 and
BAK gene expression (1.27 and 1.54 median fold change, respec-
tively). These modifications between MGUS and MM should
be interpreted with caution since PC populations in MGUS
include both normal and malignant cells. Accordingly, it has been
previously reported that normal PC in MGUS can represent up to
65% whereas in MM the percentage of normal PCs is<2% (7).
COMPARISON OF Bcl-2 FAMILY MEMBERS IN MM SUBGROUPS
Analysis of anti-apoptotic gene expression within the four major
subgroups provided evidence that the HY and CCND1 groups can
be distinguished from MAF and MMSET groups by a high expres-
sion of BCL2 and a weak expression of MCL1 (1.3 and 0.7 median
fold change, respectively), as already reported (8). Furthermore,
BCLXL allowed to discriminate HY from CCND1 patients and also
MAF from MMSET patients, since CCND1 expressed significantly
less BCLXL than HY patients (p< 0.0001 Mann–Whitney test;
Figure 3) and MMSET patients expressed significantly less BCLXL
than MAF patients (p< 0.0001 Mann–Whitney test; Figure 3).
Although BCLXL was heterogeneous among the four subtypes,
its role in MM physiopathology remained elusive. While we have
previously shown that silencing BCLXL did not alter the survival
of myeloma cell lines (9), other studies have demonstrated that
BCLXL played a role in chemoresistance (10). Of note, a high
expression of MCL1 was found in the worse prognosis groups
(MAF and MMSET) according to the essential function of Mcl-1
in MM cell survival (9, 11, 12). On the other hand, we may ques-
tion whether the lowest MCL1 levels present in the CCDN1 group
could influence its neutral outcome.
BH3-mimetic small molecules that bind to the BH3 binding
sites of anti-apoptotic proteins have been developed. Among them
ABT-199 is the newest one, characterized by its high potency
to inhibit specifically Bcl-2 (13). In agreement with the high
FIGURE 1 | Affymetrix data from a cohort of 44 MGUS and 414
untreated patients from the Arkansas Cancer Research Center were
analyzed for BCL2 (probe set 203685_at), BCL2L1 (probe set
212312_at), MCL1 (probe set 200797_s_at), BAX (probe set
208478_s_at), and BAK (probe set 203728_at) expression using the
Amazonia database (http://amazonia.transcriptome.eu/). Median
values were indicated. Statistical analyses were done using the
Mann–Whitney test.
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FIGURE 2 | Affymetrix data from a cohort of 44 MGUS and 414
untreated patients from the Arkansas Cancer Research Center were
analyzed for BIM (probe set 1553088_a_at), BBC3 (probe set
211692_s_at), BID (probe set 211725_s_at), BIK (probe set
205780_at), PMAIP1 (probe set 204285_s_at), and BAD (probe set
1861_at), expression using the Amazonia database. Median values
were indicated. Statistical analyses were done using the Mann–Whitney
test.
FIGURE 3 | Affymetrix data from untreated patients were analyzed for
BCL2, BCL2L1, and MCL1, expression using the Amazonia database in
the different molecular groups classified as follow: hyperdiploid (HY),
CCND1 (CD1+CD2), MAF, and MMSET (3). Probe sets are indicated in
Figure 1. Median values were indicated. Statistical analyses were
conducted using the Kruskall–Wallis test when more than two groups
were compared and Mann–Whitney test for the comparison between two
groups.
expression of BCL2 in CCND1 patients, we have recently demon-
strated in a small cohort of MM patients that ABT-199 sensitivity
was restricted to t(11;14) patients (14). Further analysis of a
larger cohort of MM patients for ABT-199 sensitivity could allow
identifying HY patients able to respond to ABT-199.
Strikingly, analysis of multi-domain pro-apoptotic members
showed that the worse prognosis groups MAF and MMSET dis-
played higher levels of BAX and BAK in contrast to the CCDN1
group, which expressed the lowest levels of both effectors (1.38
and 1.85 median fold change, respectively) (Figure 4). BH3-only
activators (BIM, PUMA, BID) were constantly expressed in the
four subtypes, suggesting that independently of the subtype, MM
cells are primed for death, as already reported (15, 16) (Figure 5).
Of note, Puma expression was weaker exclusively in CCDN1 group
compared to the other subgroups (0.82 median fold change). The
promiscuous binding of Bim and Puma to main pro-survival
members, associated with the fact that knockout mice for them
do not present a particular phenotype, suggest a complementary
role for these two members (17). However, based on the constant
endogenous expression of BIM and PUMA found in the four MM
subgroups, it would be pertinent to address the question whether
they have complementary roles or not in this pathology.
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FIGURE 4 | Affymetrix data from untreated patients were analyzed for BAX and BAK expression using the Amazonia database in the different
molecular groups classified as above in Figure 3. Probe sets are indicated in Figure 1. Median values were indicated. Statistical analyses were conducted as
in Figure 3.
FIGURE 5 | Affymetrix data from untreated patients were analyzed for BIM, BBC3, and BID, expression using the Amazonia database in the HY, CCND1,
MAF, and MMSET molecular groups. Probe sets are indicated in Figure 2. Median values were indicated. Statistical analyses were conducted as in Figure 3.
In contrast to BH3-only activators, sensitizers (BIK, NOXA,
BAD) were heterogeneously expressed in the different MM
subtypes. However, each MM subgroup highly expressed at least
one sensitizer (Figure 6). These results are consistent with the
fact that sensitizer BH3-only proteins may have overlapping func-
tions (18). In this respect, it was previously shown that knockout
mice for either Bik or Noxa proteins do not develop spontaneous
tumors (17, 19). Interestingly, we found that few patients in some
subgroups lacked Bik, according to our previous finding show-
ing that some MM cell lines do not express Bik at the protein
level (20). Deletions and epigenetic alterations have been shown
to contribute to the lack of Bik expression (21, 22). TEF, a PAR-
bZIP transcription factor, was identified as a direct activator of
BIK promoter (21). We have shown in MM cell lines, that Bik
was expressed only in the presence of TEF mRNA (20). However,
despite TEF expression, some cell lines did not express Bik. Alto-
gether, these results suggest that lack of Bik might be the result of
either an epigenetic alteration or a deletion, as frequently described
in other cancers (22).
In addition, NOXA allowed discriminating CCND1 from
HY patients (5 median fold change) and also MMSET from
MAF patients (6.68 median fold change) (Figure 6). Although
the difference of NOXA expression was impressive among the
four subtypes, its role in MM physiopathology remained to be
determined.
Hyperdiploid patients expressed significantly higher levels
of BAD than all other subgroups (1.35 median fold change)
(Kruskall–Wallis p< 0.0001), which may be explained by the
localization of BAD on chromosome 11q1 (Figure 6). Indeed,
chromosome 11 trisomy is one the most frequent anomaly in the
HY subgroup (23).
CONCLUDING REMARKS
Noteworthy, our analysis demonstrated that the combined pro-
file of the three anti-apoptotic molecules (Bcl-2, Bclx-L, and
Mcl-1) was sufficient to discriminate the different MM molec-
ular groups. The CCDN1 subgroup was identified as a particular
entity, characterized by a BCL2high MCL1low and a low expres-
sion of pro-apoptotic effectors and BH3-only (PUMA, BIK, and
BAD) with the exception of high expression of NOXA. Since
Noxa interacts only with Mcl-1, which is weak in this subtype,
we can hypothesize that the anti-apoptotic function of Mcl-1 is
totally neutralized by Noxa and that this subtype relies mainly
on Bcl-2 for survival. Altogether, the apoptotic machinery of
this myeloma subtype is very different from that of other sub-
types, suggesting that specific therapeutic approaches should be
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FIGURE 6 | Affymetrix data from untreated patients were analyzed for BIK, PMAIP1, and BAD expression using the Amazonia database in the HY,
CCND1, MAF, and MMSET molecular groups. Probe sets are indicated in Figure 2. Median values were indicated. Statistical analyses were conducted as in
Figure 3.
investigated to target CCDN1 patients. We can also hypothesize
that the specificity of this subgroup may reflect a specific ori-
gin of malignant PC immortalization. This is also supported by
the fact that patients harboring a t(11;14) have a high prevalence
of IgM isotype and represent a distinct biological and clinical
subgroup (24). Furthermore, recurrent translocations also cor-
related with particular features (25). Indeed, t(11:14) transloca-
tions exhibited a mature lymphoplasmocytoid morphology with
a higher incidence of non-secretory MM. In contrast, t(4;14)
MM subtype revealed a morphology of immature plasma cells
with a significant amount of plasmablasts (25, 26). The HY sub-
group shares some similarities with CCND1 in the expression
pattern of Bcl-2 family members, particularly high BCl2 and
low MCL1 levels. However, HY patients expressed higher levels
of pro-apoptotic members (BAX, BAK, and BAD) than those
of the CCND1 subgroup (Figures 5 and 6). This could favor
the apoptotic response to chemotherapy and therefore explain in
part the better outcome of these patients. In contrast, MAF and
MMSET subgroups differ from CCDN1 and HY in the expres-
sion of anti-apoptotic members and were characterized by low
BCL2 and high MCL1 levels. Surprisingly, MAF and MMSET
subgroups expressed high level of effectors, particularly Bak, sug-
gesting their ability to trigger an effective drug response. It will
be intriguing to define whether the high expression of effec-
tors in MAF and MMSET subgroups may be related to the fact
that bortezomib-containing regimens could overcome the poor
prognosis associated with t(4;14) (27). Paradoxically, these sub-
groups have the poorest outcome, highlighting a potential role of
Mcl-1 in chemoresistance. A potential and interesting approach
to target efficiently MAF and MMSET patients would be to use
pharmacological inhibitors of Mcl-1, which are currently under
development (28).
To summarize, our analysis supports the notion that MM
heterogeneity extends to the composition of the Bcl-2 fam-
ily content in each MM subgroup, which should be taken
into account for therapeutic intervention in the new approach
of personalized therapies. Finally, a better knowledge of Bcl-
2 expression patterns may be relevant to address the origin of
malignant PC.
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